The Ministry of Health of the Russian Federation has awarded Biocad marketing authorization for its interferon beta-1a biosimilar, a knockoff of Merck’s RebifA that is a key component in treatment of relapsing-remitting multiple sclerosis and included in all international recommendations and protocols. BIOCAD started the development program for interferon beta-1a biosimilar in 2012 and it took almost 5 years to run all the development phases, including pre-clinical/clinical studies and registration.